curriculum vitae debra a. tonetti, ph.d. - … · laboratory of dr. v. craig jordan ... penny...
TRANSCRIPT
CURRICULUM VITAE Debra A. Tonetti, Ph.D.
Department of Biopharmaceutical Sciences College of Pharmacy
University of Illinois at Chicago (312) 413-1169 (Office)
(312) 996-1698 (Fax) [email protected]
PROFESSIONAL EXPERIENCE Feb 2017-present Interim Head Department of Biopharmaceutical Sciences 2016-present Inventor and Co-Founder, TTC Oncology, LLC 2007-present Associate Professor of Pharmacology, with tenure
Department of Biopharmaceutical Sciences 2003-present Member of the Graduate College
University of Illinois at Chicago
2001- present Cancer Center Member University of Illinois at Chicago
2001-2007 Assistant Professor of Pharmacology
Department of Biopharmaceutical Sciences 2002-2008 Affiliate Faculty, Center for Pharmaceutical Biotechnology
University of Illinois at Chicago 1996-2001 Research Assistant Professor
Robert H. Lurie Comprehensive Cancer Center Northwestern University Medical School
1994-1996 Senior Research Associate
Laboratory of Dr. V. Craig Jordan Robert H. Lurie Cancer Center Northwestern University Medical School
1989-1994 Enrico Fermi Postdoctoral Fellow
Laboratory of Dr. Eli Huberman Center for Mechanistic Biology and Biotechnology Argonne National Laboratory
EDUCATION 1984-1990 Doctor of Philosophy
Laboratory of Dr. Robert V. Miller Department of Molecular and Cellular Biochemistry Loyola University of Chicago
1983-1985 Master of Science
Laboratory of Dr. Howard M. Laten Department of Biology Loyola University of Chicago
1977-1980 Bachelor of Science
Major: Biology; Minor: Chemistry Northern Illinois University
FUNDING Active 2017-2018 G1 Therapeutics Sponsored Research Agreement
Project title: Discovery of New Partners for Combination Therapy with G1T48 Costs: $350,000 Funding period: 6/01/17-5/31/18 Role: Co-PI
2015-2018 NIH RO1CA188017 (Thatcher)
Project title: Partial Agonists at Estrogen Receptor α for Breast Cancer Therapy Total Costs: $ 1,698,578.00 Funding Period: 05/01/15-04/30/18 Percent effort and salary: 10% Role: Co-Investigator
2015-2017 University of Illinois Foundation Philanthropic Gift
Project title: Lung Cancer Patient-Derived Xenografts Total Costs: $100,000
Funding Period: 7/15/15-11/14/17 Role: PI
2015-2020 NIH/NCIR01 CA200669 (Frasor)
Project title: Estrogen Receptor and NFkB Crosstalk in Breast Cancer Total Costs: $194,260 (DT) Funding period: 9/01/15-8/31/20 Role: Co-I
2017-2022 NIH/NCI CA216410 (Rana) Project title: Developing Nano Technology for HER2 Directed
Therapy Total Costs: $250,133/$2,290,434 Funding period: 3/01/17-2/28/22 Role: Collaborator
Past 2016-2017 Chicago Biomedical Consortium Tonetti (PI)
Selective Inhibition of Tamoxifen-Resistant Breast Cancer Cell Growth by Single Agents in Combination High Throughput Screening Supplemental Grant Program Total costs: $40,000 Funding period: 3/1/16 – 8/31/17
2016-2017 Chicago Biomedical Consortium (Tonetti/Thatcher, Co-PIs)
PDX Pilot Project title: Therapeutic efficacy of novel SEM and SERD drugs in breast cancer PDXs
Costs: $25,000 Funding period: 3/1/16 – 2/28/17
2010-2015 NIH Supported Centers for Population Health and Health Disparities
Project title: DNA Methylation and Differential Breast Cancer Aggressiveness by Race/Ethnicity (Project 3) Total Costs: $9,999,770 Funding Period: 4/01/10-3/31/15 PI: R. Warnecke Percent effort and salary: 5% Role: Co-Investigator
2014 UIC Cancer Center Pilot Grant (PI)
Project title: Establishment of a relevant breast cancer pre-clinical model: Patient-Derived Xenografts Total Costs: $50,000 Funding Period: 03/01/14-02/28/15 Percent effort and salary: 5% effort and 0% salary Role: PI
2013 Proof of Concept
Project title: SEMs for the Treatment of Tamoxifen-Resistant Breast Cancer Total Costs: $50,000 Funding Period: 01/07/13-06/30/15 Percent Effort: 5% Role: Co-PIs Debra Tonetti, Greg Thatcher. Lucy Chen
2013 CCTS Pilot Grant CCTS0413-04
Project Title: Mechanism of action of TTC-352 for the treatment of endocrine-resistant breast cancer Funding period: 05/01/13-04/30/14 Total Costs: $30,000 Percent Effort: 10% Co-PI: Gregory Thatcher Role:PI
2010-2013 Avon Foundation
Project title: Breast Cancer Risk Prediction Based on a Parity-Associated Gene Signature Total Costs: $300,000 Funding Period: 7/1/10-6/30/13 (no cost extension) Percent effort and salary: 10% PI: D.A. Tonetti
2007-2013 NIH/NCI R01 CA122914-05
Project title: PKC Alpha as a Marker for Logical Therapeutic Approaches to Breast Cancer Total Costs: $2,242,342 Funding Period: 06/01/07-04/30/13 (2013 no cost extension) Percent Effort and Salary: 20% Role: PI
2010-2012 Chicago Biomedical Consortium Catalyst Award
Project Title: Application of 3D Cell Culture and Signaling Arrays in a Breast Cancer Model Funding Period: 2/01/10-1/31/12 Total Costs: $100,000 Percent Effort: 5% Co-PIs: Debra Tonetti and Lonnie Shea Role: Co-PI
2006-2010 Avon Foundation
Project title: Molecular Evidence of the Role of Lobular Involution in Pregnancy-Associated Breast Cancer Total Costs: $650,000 Funding Period: 08/31/06-6/30/10 Percent Effort and Salary: 10% Role: PI
2007-2012 NIH, NICHHD, 1K12HD055892-01
Building Interdisciplinary Research Careers in Women’s Health Total Costs: $2.5M Funding Period: 9/1/2007 – 8/31/2012 PI: Stacie Geller Role: Mentor
2008-2009 IDPH, Penny Severns Breast, Cervical and Ovarian Cancer Research
Fund Project Title: Clinical Value of Aromatase Inhibitor Therapy in PKCα Overexpressing Breast Cancer Total Costs: $60,000 Funding Period: 07/01/08-06/30/09 % Effort and Salary: 10% Role: PI
2004-2009 NIH, NIGMS T32 BM070388
Pharmacological Sciences Training Program Total Costs: $990,336 Funding Period: 07/01/05-06/30/09 PI: AB Malik Role: Preceptor
2005-2007 Susan G. Komen Breast Cancer Foundation
Total Costs: $250,000 Funding Period: 05/01/05-04/30/07 Project title: Mechanism of Protein Kinase C Alpha-Mediated Tamoxifen Resistant Breast Cancer % Effort and Salary: 10% Role: PI
2004-2006 NIH/NCI P50 CA106743
Pilot Study UIC Centers for Population Health and Health Disparities Total Costs: $80,000 Funding Period: 08/15/04-08/14/06 Project Title: The role of PKCα and ERβ in aggressive breast cancer in African-American breast cancer patients Role:PI
2001-2005 NCCAM RO1 CA96517 (Botanical/Drug Interactions)
Andreas Constantinou (PI) Award: $1,320,666 Project title: Mechanism(s) of antitumor action of tamoxifen and soy Funding Period: 08/01/01-07/31/04 (8/01/04-7/31/05 no cost)
% Effort and Salary: 20% Role: Co-Investigator
2002-2005 NIH R21 CA97045 (Exploratory Studies in Cancer Detection, Prognosis and Prediction) Total Costs: $336,116 Funding Period: 9/01/02-8/31/05 (9/1/04-8/31/05 no cost) Project Title: PKCα overexpression as a marker in tamoxifen-resistant breast cancer % Effort and Salary: 10% Role: PI
2003-2004 Vahlteich Research Award, College of Pharmacy, UIC
Total Costs: $27,000 Funding Period: 07/01/03-06/30/04 Project title: “Mechanism of Estradiol-Mediated Regression of Protein Kinase C Alpha-Overexpressing Breast Tumors” Role: PI
2002-2003 University of Illinois at Chicago Campus Research Board
Total Costs: $15,000 Funding Period: 07/01/02-6/30/03 Project title: “PKC-Mediated Antitumor Effect of E2 in TAM-Resistant Breast Cancer” Role: PI
2000-2001 Avon Breast Cancer Crusade, Avon Products Foundation
03/07/00-03/06/01 Total Costs: $50,000 Title: “Protein Kinase C as a Mechanism of Antiestrogen Resistance” Role: PI of Project Overall PI: Monica Morrow, M.D.
1998-2001 NIH NCI R01 CA79847
12/08/98-11/3/01 Total Costs: $433,590 Title: “The Role of Protein Kinase C in Tamoxifen-Stimulated Tumor Growth” % Effort and salary: 65% Role: PI
1997-1998 American Cancer Society Illinois Division
Total Costs: $34,909 Title: “Tamoxifen-Resistant Breast Cancer and PKC Isozyme Expression” % Effort and salary: 80% Role: PI
ENTREPRENEURIAL ACTIVITIES 2016-present Co-Founder, TTC Oncology, LLC TTC Oncology introduces TTC-352, a Selective human Estrogen Receptor Partial
Agonist (ShERPA) designed to treat metastatic ER-positive breast cancers that have recurred following first-line endocrine therapy and palbociclib. FDA IND approval for a Phase I clinical trial (July 2017). Company founders and inventors: Drs. Debra Tonetti and Gregory Thatcher
2016 License Agreement: G1 Therapeutics
Tonetti/Thatcher licensed an orally bioavailable Selective Estrogen Receptor Downregulator (SERD) to G1 Therapeutics (G1T48) with a $500,000 signing fee. G1 is planning to combine a CDK4/6 inhibitor (G1T38) with the G1T48 SERD as a potentially best-in-class regimen for patients with ER+, HER2- breast cancer. G1T48 is on track for IND filing in 4Q17.
Clinical Trials
Phase II Study of Estradiol Therapy in Metastatic Breast Cancer and Protein Kinase C as a Potential Biomarker (Lucy Chen, M.D., PI) Role: Co-I Study TTC-352-101: Phase 1 Study of TTC-352 in Patients with Metastatic Breast Cancer Progressing on Endocrine Therapy (TTC Oncology, LLC, co-Founder). Accruing Dec. 2017.
Patents Awarded: Compositions and Methods for Treating Estrogen-Related Medical Disorders
13848485.8 – 1453 PCT/US2013066699 US Patent No. 9,475,791
Applications: Benzothiophene-Based Selective Estrogen Receptor Downregulator Compounds.* Application 15/375,049
Combination Therapy for the Treatment of Cancer* Application 62/5443,588 Novel benzothiophene based selective estrogen receptor downregulators and mixed function downregulators* Application 62/411,988
*Licensed to G1 Therapeutics 2015-present Leader of Patient-Derived Xenograft (PDX) effort at UIC
UI Health Cancer Center’s Breast Cancer Research & Lung Cancer Working Groups
Inventions/Disclosures UIC-2017-109 Combination therapy of selective down-regulators and bromodomain inhibitors for
advanced estrogen receptor positive breast cancer UIC-2017-108 Combination therapy of selective down-regulators and PLK3 inhibitors for advanced
estrogen receptor positive breast cancer UIC-2017-082 Combination therapy of selective estrogen down-regulators and CDK4/6 inhibitors for
advanced estrogen receptor positive breast cancer UIC-2017=032 Radiotracer Imaging UIC-2017-028 Novel Benzothiophene-based selective estrogen receptor downregulators & mixed-
function downregulators UIC-2017-023 Topical Sebum Diagnostic UIC-2016-059 Breast Cancer Model for endogenous tamoxifen resistance
(Exclusive License to Abbvie) UIC-2016-058 Breast Cancer Cell Model for PKC alpha overexpression and tamoxifen resistance
(Exclusive License to Abbvie) UIC-2016-048 Novel Benzothiophene-based selecetive estrogen receptor downregulators UIC-2013-113 Protein Kinase C Alpha is a predictive biomarker for response to estradiol in
endocrine-resistant breast cancer UIC-2013-044 Therapies associated with modulation and mimicry of hormone actions UIC-2010-028 Increased expression of inflammatory genes in pregnancy-associated breast cancer UIC-2010-027 PKCa-overexpressing breast cancer is noinvasive and nonmigratory despite tamoxifen-
resistance UIC-2010-026 Gene expression patterns in the human breast after pregnancy UIC-2010-025 Estradiol induced regression of T47D:A18/PKCa tumor involves translocation of
estrogen receptor alpha from the nucleus to the cytoplasm UIC-2010-024 2-(4-hydroxyphenyl)-benzo[b]thiophen-6-ol, an estrogen-like compound induces
apoptosis in T47D/PKCa breast cancer cells.
HONORS 1984-1985 Basic Science Fellowship, Loyola University of Chicago 1988-1989 University Dissertation Fellowship, Loyola University of Chicago 1989 Enrico Fermi Scholar, Argonne National Laboratory 2003-2004 Vahlteich Scholar, College of Pharmacy, UIC
PROFESSIONAL ASSOCIATIONS Member, American Association for Cancer Research (AACR) Member, American Society for Pharmacology and Experimental Therapeutics (ASPET) Member, Women in Cancer Research Affiliate Member, American Society of Clinical Oncology (ASCO)
SERVICE Councilor, Great Lake Chapter of the American Society for Pharmacology and Experimental Therapeutics (ASPET) (2009-2010) Editorial Board Member, Breast Cancer – Targets and Therapy (2010-present) Editorial Board Member, International Journal of Breast Cancer (2009-present) Review Editor, Frontiers in Cancer Genetics (2011-present) Guest Editor, International Journal of Breast Cancer, Special Issue on New Concepts in Resistance to Breast Cancer Treatment Manuscript Reviewer (Ad Hoc): Biomarkers, BMC Cancer, British Journal of Cancer, Breast Cancer Research, Breast Cancer Research and Treatment Cancer, Cancer Research, Carcinogenesis, Cancer Biology & Therapy, Clinical Breast Cancer, Clinical Cancer Research, Cancer Chemotherapy and Pharmacology Cancer Letters, Combinatorial Chemistry & High Throughput Screening, IUBMB Life, Endocrinology, Endocrine-Related Cancer, Hormones and Cancer, Molecular Carcinogenesis, Molecular Cancer Research, Molecular Cancer Therapeutics, Nature Communications, Nutrition and Cancer, Oncogene, Oncogenesis, Oncotarget, Oncology Research, PLOS One, Steroid Biochemistry & Molecular Biology Study Sections/Review Panels: Scientist Reviewer, END-2 panel Department of Defense Breast Cancer Study Section 1998- 2000, 2004, 2009-2010. Scientist Reviewer, MBG panel Department of Defense Breast Cancer Study Section, 2005 and 2007-2008 Member, American Cancer Society Research Advisory Committee, Illinois Division 2000-2004. NIH NCI Ad Hoc Committee Member (2003), Program Project Site Visit Grant Reviewer, Sheffield Hospital Charitable Trust, University of Sheffield, UK, Dec. 2003. NIH NIA Ad Hoc Committee Member (2004), Program Project Site Visit Peer Review Panel Member, Penny Severns Breast, Cervical and Ovarian Cancer Research
Fund, Illinois Department of Public Health, Office of Women’s Health 2006-2007.
Scientist Reviewer, OCRP Concepts, Department of Defense, Online Reviewer, 2007 Scientist Reviewer, IPA-2 panel Department of Defense Breast Cancer Study Section, 2009 Ad-Hoc Member Scientific Advisory Board, Avon Foundation Grant Review, 2009-2010, 2012. NIH/CSR Special Emphasis Panel ZRG1 BDA-A 58, Mail Reviewer, July 2009 Scientist Reviewer, BCRP Concepts CET-3 Panel, DOD, Online Reviewer, 2010 Scientist Reviewer, BCRP CET2 Panel, Department of Defense, 2012, 2013 Scientist Reviewer, BCRP CET5 Panel, Department of Defense, 2015 Scientific Review Board, Chicago Biomedical Consortium, 2012-present. External Advisory Panel for Breast Cancer SPORE, Northwestern University, 2012 Grant Reviewer, University of Svöde, 2012 Grant Reviewer, University of Pennsylvania State University Formula Grant 2013 Grant Reviewer, Florida Department of Health and ORAU Grant Review 2015, 2016 Grant Reviewer, Breast Cancer NOW, Barts Cancer Institute,
Queen Mary University of London, 2017 University Review 2007 Graduate and Professional Student Research Forum Judge Internal Research Grants Competition at the University of Illinois
College of Medicine at Rockford 2010-2015 Chancellor's Supplemental Graduate Research Fellowship Program Reviewer 2011, 2014, 2015 College of Pharmacy Research Days, Poster Judge 2014-2016 Cancer Center Research Day, Poster Judge TRAINING EXPERIENCE Member of Dissertation Committee for the following students:
Joanna Burdette, Dept. of Pharmacognosy, UIC. Ph.D., 2003 Nicole Darack, Molecular & Cellular Biochemistry, Loyola University, Ph.D., 2004 Rachel Ee, Biopharmaceutical Sciences, Ph.D., 2004 Hong Liu, Dept of Medicinal Chemistry, UIC. Ph.D., 2005 Jovita Tauro, Biopharmaceutical Sciences, UIC, Ph.D., 2005 Joaquina Mascarenas, Biopharmaceutical Sciences, UIC 2006 Adina Stanculescu, Center for Pharmaceutical Biotechnology, UIC, Ph.D. 2006 Lei Tang, Biopharmaceutical Sciences, UIC, Ph.D. 2006 Cassia Overk, Dept of Medicinal Chemistry, UIC, Ph.D. 2007 Jieun Yun, Biopharmaceutical Sciences, Ph.D. 2007 Deepali Vartak, Biopharmaceutical Sciences, UIC, Ph.D. 2009 Zhican Wang, Dept of Medicinal Chemistry, UIC, Ph.D. 2009 Songpil Cho, Biopharmaceutical Sciences, UIC, Ph.D. 2009 Kuanwei Peng, Dept. of Medicinal Chemistry, UIC, Ph.D. 2009 Zhican Chen, Dept of Medicinal Chemistry, UIC, Ph.D. 2009 Bolan Yu, Dept of Medicinal Chemistry, UIC, Ph.D. 2010 Yalda Afshar, Physiology and Biophysics, MD/Ph.D. 2010 Gwendolyn D’Souza, Biopharmaceutical Sciences, UIC, Ph.D. 2010
Ramy Essam Abdelhamid, Dept of Medicinal Chemistry, UIC, Ph.D. 2011 Teshome Gherezghiher, Dept. of Medicinal Chemistry, UIC, Ph.D. 2011 Indraneel Kundu, Dept. of Medicinal Chemistry, UIC, Ph.D. pending Cheng-Fen (Terri) Chen, Biopharmaceutical Sciences, UIC, Ph.D. 2011 Sumit Sahni, Dept. of Medicinal Chemistry, UIC, Ph.D. 2011 Marianna Halasi, Biochemistry and Molecular Genetics, Ph.D.2012 Tsui-Ting Ho, Biopharmaceutical Sciences, UIC, Ph.D. 2012 Kinnari Mehta, Loyola University, Ph.D. 2013 Bradley Michelson, Dept. of Medicinal Chemistry, UIC, Ph.D. 2013 Maoyu Peng, Dept. of Molecular Genetics, UIC, Ph.D. 2013 Yang Yang, Biopharmaceutical Sciences, UIC, Ph.D. 2013 Madhubhani Hemachandra, Dept. of Medicinal Chemistry, UIC, Ph.D. 2013 Yu Zhang, Biopharmaceutical Sciences, UIC, Ph.D. 2015
Atieh Hajirahimkhan, Dept of Pharmacognosy, UIC, Ph.D. 2016 Brian Shy, Dept of Molecular Genetics, UIC Ph.D. pending Hitisha Patel, Dept. of Medicinal Chemistry, UIC, Ph.D. 2016 Rui Xiong, Dept. of Medicinal Chemistry, UIC, Ph.D., 2016 Goda Muralidhar, Biopharmaceutical Sciences, UIC, Ph.D. 2016 Lauren Gutgesell, Dept of Medicinal Chemistry, UIC, Ph.D., pending Yilun Sun, Biopharmaceutical Sciences, UIC, Ph.D., pending Joelle Sachs, Biopharmaceutical Sciences, UIC, Ph.D., pending
Past M.S. Graduate Student:
Huifang Han, M.S., July 2008-2011 Past Ph.D. Graduate Students:
Yiyun Zhang, Ph.D., August 2008 Current position: Postdoctoral Fellow, Harvard Medical School
Bethany White, Ph.D., July 2012 Current position: Research Assistant Professor, Northwestern University
Mary Ellen Molloy, Ph.D., January 2014 Current position: Postdoctoral Fellow, Harvard Medical School
Thao Nguyen Pham, Ph.D., August 2016 Current position: Postdoctoral Fellow, Northwestern University
Current Ph.D. Graduate Student: Lauren Gutgesell, Co-mentored with G. Thatcher, Medicinal Chemistry
Pharm.D. Students:
Meghan Hayes, July 2007-2009 Rutu Joshi, June 2009-June 2010 Sybille Lupee, July 2010-2012 Sabrina Sanchez, Jan 2013-August 2013 Jenny Le, May 2013-September 2013 Lelas Shamaileh, May 2016-Jan 2017
Undergraduate Volunteers: Ahmed Mahafzah, pre-pharmacy, Aug. 2004-2005 Mary Ellen Molloy, pre-pharmacy, July 2007-May 2008
Past Postdoctoral Fellows:
Szilard Asztalos, Ph.D., 2006-2012 Mahducchanda Kundu, Ph.D., 2008-2011 Mohamed Nasr, Ph.D. 2004-2005 Xin Lin, Ph.D., 2003- 2004 Yasmin Ahmed, Ph.D., 2000-2001
Past Masters Students: Northwestern University Center for Biotechnology Graduate Program
Anna Berdine, M.S., 1997 graduate Wendy Grdina, M.S., 1998 graduate Heather Schurz, M.S., 1998 graduate David Fournier, M.S., 1999 graduate Robyn Pike, M.S., 2001 graduate Jessica Manela, M.S., 2001 graduate
Summer Students: Northwestern University Medical Students
Jason Bradfield, summer, 1999 Sharon Shen, summer, 2000 Connie Rhee, summer 2001
Northwestern University Pre-med undergraduate student
Jonathan Berger, summers 1997 and 1999 Whitney Young Magnet High School Student, American Cancer Society Summer Research Program:
Margaret Sharp, Summer 2003 Urban Pipeline Program Under-represented Minority High School Pathways to Pharmacy/Science Program
Summer 2010 and 2011 American Society for Pharmacology and Experimental Therapeutics (ASPET) Summer Undergraduate Research (SURF) Students: Lisa Gutgesell, Summer 2016 Allyson Schreiber, Summer 2017 Biopharmaceutical Sciences, Pharmaceutical Biotechnology Center, MD/Ph.D Rotation Students Aarti Lalla (BPS,2002) Qi Shen (PBC, 2003) Denise Holzle (PBC, 2004)
Sok Bee Lee (BPS, 2005) Su-Young Choi (PBC, 2005) Zhican Chen (PBC, 2005) Jin Wha Song (PBC, 2006) Lila Gollogly (MSTP, MD/Ph.D. 2006) Tsui-Ting Ho (BPS, 2006) Huifang Han (BPS, 2008) April Szafran (MD, 2009) Ying Gao (BPS, 2010) Lamiaa El-Shennawy (BPS, 2011) Thao Pham (BPS, 2011) Amanda Mennie (MSTP, MD/Ph.D. 2012) Joelle Sachs, (BPS, 2012) Dulari Jayawardena (BPS, 2014) Ashita Nair (BPS, 2015) Yukuang Gau (BPS, 2016) Joseph Olewinski (BPS 2017) Carlo Rosales (MCP, 2017) Monica Sheinin (BPS, 2017) Ziwei Zhang (BPS, 2017)
2004-2006, 2014 Coordinator of Campus-Wide Breast Cancer Journal Club
2008-2010 NIH K12 Award Mentor, Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) Hyungyoung Jeong, Pharm.D.,Ph.D., Assistant Professor, Departments of Pharmacy Practice and Biopharmaceutical Sciences, UIC College of Pharmacy
TEACHING ACTIVITES Graduate
Spring, 2002 Introduction to Pharmaceutical Research (PMPC 495) 2 hours of lectures
Spring, 2003-present Biopharmaceutical Sciences II (BPS 502), Course Co-Coordinator
17 hours of lectures Spring, 2002-2005 Biological Evaluation of Natural Products (PMPG 480)
1 hour lecture 2003-2005 2009-2010 Departmental Seminar (BPS 595), Course Co-Coordinator 2001-present Research in Biopharmaceutical Sciences (BPS 593)
Spring, 2004 Fall, 2006-2009 Pharmacogenomics (BPS 555)
1 hours lecture, Genes and Genetics Spring, 2005 Advanced Cancer Epidemiology, School of Public Health
2 hour lecture, Breast Cancer Therapies Spring, 2005 Tumor Cell Biology, Northwestern University
1 hour lecture, Breast Cancer Therapies and Mechanisms of Action Fall, 2006 Neuroendocrinology (ANAT 554)
2 hour lecture, ER and SERMs 2008-present BPS/MDCH/PMPG 553, Cancer Biology and Therapeutics
Course originator and Co-Coordinator 6 hours lecture
Fall 2010 PATH 510, Pathobiology of Cancer
1.5 hour lecture Professional Fall, 2002 BPS 380, Undergraduate Research in Biopharmaceutical Sciences
Asha Sztark, P2 student Spring, 2004 Erika Meredith, P1 student Fall 2001-2006 Clinical Pharmacology (BPS 470)
1 hour lecture, SERMs Fall 2003-2014 Phar 321, Drug Delivery Systems I: Pharmaceutical Dosage Forms
and Drug Delivery Systems 2 hours lecture, GI Physiology & Drug Absorption; Drug Metabolism & Pharmacogenomics
Spring 2006-2007 Phar 404, Principles of Drug Action and Therapeutics IV
1 hour lecture, Pharmacology of Female Sex Hormones Spring 2006-2007 2010 PMPR 355, Research Seminar
1 hour lecture Spring 2008-2016 Phar 404, Principles of Drug Action and Therapeutics IV
Course Coordinator 1 hour lecture, Pharmacology of Female Sex Hormones
Spring 2015-present Phar 322 Drug Delivery Systems II: Pharmaceutical Dosage Forms and Drug Delivery Systems 2 hours lecture, GI Physiology & Drug Absorption; Drug Metabolism &
Pharmacogenomics
Fall 2016-present Phar 410 Integrated Physiology 3 hours lecture, Thyroid Hormones
Fall 2017 PhLAMES Advisor Spring 2019 Phar 509 PDAT 9:Hematology/Oncology upcoming Course Co-Coordinator COMMITTEES University Spring, 2005 Fall 2009-2012 Senator, Senate of the University of Illinois at Chicago
2009/2010 Member, Senate Committee on Student Affairs 2010/2011 Chair, Senate Committee on Student Affairs
Fall 2007 Member, Membership Subcommittee of the Cancer Center Transition
Advisory Membership Committee Spring/Fall 2008 Member, Search Committee for Associate Director of Cancer Control,
Population Science and Education, UIC Cancer Center 2010-present Admissions Committee, Medical Scientist Training Program
2015-present Member, Cancer Center Protocol Review Committee
College
2002 Member, College of Pharmacy Strategic Planning Committee
2002-2003 Member, Student/Faculty Relations Committee
2003-2004 Member, Research Committee 2004-2010 Member, Executive Committee, Pharmacological Sciences Training
Program 2005-2010 Member, Advisory Committee, UIC/NIH Center for Botanical Dietary
Supplements Research 2006 Member, Salary Bonus/Award Committee
2006-2007 Member, ACPE Self-Study Subcommittee
2006-2007 Member, Student Disciplinary Committee 2007 Chair, Vahlteich Award Committee 2008-2009 Member, Academic Standing Committee
2007-2014 Member, COP Research Advisory Committee 2009-present COP Representative to Research Resources Center Exec. Advisory Panel 2010, 2015 Vahlteich Award Committee 2009-2016 COP Executive Committee
2012/2014 Member, BPS Forensics Faculty Search Committee
2015/2016 Co-Chair, COP Promotion and Tenure Committee 2016 Member, Department Merger Committee 2017 BPS Department Head Search Committee 2017-present Administrative Officers
Departmental 2002-present Member, Student Oversight and Exam Committee 2002-2006 Chair, Department Brochure and Website Committee
2002-2005 Chair, Graduate Program Brochure Committee 2003-2017 Member, Graduate Committee
2003-2005 2006-2008 2009-2012 2013-2017 Member, Department Advisory Committee 2005-2010 Member, BPS Faculty Search Committee 2007 Member, CBP and BPS Joint Faculty Search Committee
2008-2010 Chair, Seminar and Journal Club Committee
2008-2009 Member, Bi-Laws Committee
2008-2009 Member, Curriculum Committee 2008-2009 Member, Publications Committee 2012 Member, Forensic Science Faculty Search Committee 2014-2016 Member, BPS Faculty Search Committee INVITED LECTURES May 25-28, 1997 Antiestrogen stimulated human endometrial cancer growth; laboratory and
clinical considerations. The 13th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology. Monaco.
January 25, 1999 The Role of Protein Kinase C Alpha Overexpression in Tamoxifen-
Resistant Breast Cancer. Department of Molecular and Cellular Biochemistry, Loyola University Medical Center, Maywood, IL.
April 7, 1999 The Role of Protein Kinase C Alpha Overexpression in Tamoxifen-
Resistant Breast Cancer. Department of Urology, Northwestern University Medical School, Chicago, IL.
April 6, 2001 Investigation of the PKC Signal Transduction Pathway as it Relates to
Tamoxifen-Resistant Breast Cancer. Department of Pharmaceutics and Pharmacodynamics, College of Pharmacy, University of Illinois at Chicago.
October 17, 2002 The Role of the PKC Signaling Pathway in Tamoxifen-Resistant Breast
Cancer. Center for Pharmaceutical Biotechnology, College of Pharmacy, University of Illinois at Chicago.
April 28, 2003 PKCα Overexpression May Predict Tamoxifen Treatment Failure. Rush-
UIC-Stroger Joint Breast Cancer Conference, University of Illinois at Chicago.
March 10, 2004 PKCα Over-Expression as a Marker of Tamoxifen-Resistant Breast Cancer.
Frontiers of GI Research Seminar, Section of Digestive Diseases, Department of Medicine, University of Illinois at Chicago.
May 24, 2004 Hormonal, Biological and Chemotherapeutic Approach to Breast Cancer
Treatment. Midwest Association for Toxicology and Therapeutic Drug Monitoring, Arlington Heights, IL.
November 8, 2004 PKC Alpha May Be a Predictive Marker in Tamoxifen Resistant Breast
Cancer: Implications for Therapy. Visiting Professor Lecture, Rush
Medical College, Department of Pathology, Chicago, IL. April 11, 2005 PKCα Overexpression in Breast Cancer as a Predictor for Tamoxifen and
Aromatase Inhibitor Treatment Failure: Opportunities for Alternative Therapeutic Strategies. Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL.
July 22, 2005 PKCα Overexpression in Breast Cancer as a Predictor for Tamoxifen and
Aromatase Inhibitor Treatment Failure: Opportunities for Alternative Therapeutic Strategies. Elkin Cancer Biology Seminar Series, Emory Univ. School of Medicine, Winship Cancer Institute, Atlanta, GA.
April 28, 2006 Signal Transduction Mechanisms Mediated by PKCα Overexpression in
Human Breast Cancer Models. Physiology & Biophysics Department, College of Medicine, University of Illinois at Chicago.
November 9, 2006 Molecular Evidence for the Role of Lobular Involution in Pregnancy-
Associated Breast Cancer. Avon Foundation Prevention Research Initiative Symposium. New York, N.Y.
October 11, 2006 Prognostic Factors in Breast Cancer: Preclinical Models of Breast Cancer
with Potential Translation to the Clinic. Biopharmaceutical Sciences Seminar Series, University of Illinois at Chicago.
March 14, 2007 Signal Transduction Mechanisms Mediated by PKCα Overexpression in
Breast Cancer. Department of Biology, Loyola University Chicago, Chicago, Illinois.
October 8, 2007 Tamoxifen and Soy Effects in Tamoxifen-Resistant Tumors in Mice.
Molecular Targets for Cancer Prevention, Diagnosis and Treatment, an International Conference. Lemesos, Cyprus.
November 12, 2007 Molecular Evidence for the Role of Lobular Involution in Pregnancy-
Associated Breast Cancer. Avon Foundation Prevention Research Initiative Symposium. Houston, TX.
February 20, 2008 The Role of Lobular Involution in Pregnancy-Associated Breast Cancer.
Breast Cancer Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago.
February 13, 2009 Molecular Evidence for the Role of Lobular Involution in Pregnancy-
Associated Breast Cancer. Avon Foundation. Prevention: Research and Strategies for the 21st Century. Miami, FL.
March 25, 2009 A Clinically Relevant Tamoxifen-Resistant Breast Cancer Model Sensitive to
Estradiol-Induced Tumor Regression. Department of Biochemistry and
Molecular Genetics, College of Medicine, University of Illinois at Chicago. November 20, 2009 Gene Expression in the Human Breast After Pregnancy: Evidence of Protection
or Increased Risk of Breast Cancer? Cancer Center Research Seminar, Rush Medical College, Chicago, IL.
January 14, 2010 Gene Expression in the Human Breast After Pregnancy: Evidence of
Protection or Increased Risk of Breast Cancer? Carcinogenesis/Chemoprevention Program,Cancer Center, UIC, Chicago, IL.
October 15, 2010 Gene Expression in the Human Breast After Pregnancy: Evidence of
Protection or Increased Risk of Breast Cancer? Department of Pharmacology, Midwestern University, Downers Grove, IL.
November 3, 2010 Prognostic Factors in Breast Cancer: Preclinical Models with Potential
Translation to the Clinic. Medical Scientist Training Program Lunch Seminar Series, UIC, Chicago, IL.
March 2, 2011 Breast Cancer Risk Prediction Based on a Parity-Associated Gene Signature.
Breast Cancer Prevention and Treatment Research Forum, Avon Foundation for Women, Apella at Alexandria Center for Life Science, New York, NY.
March 25, 2011 A Clinically Relevant Tamoxifen-Resistant Breast Cancer Model: Potential
Therapeutic Opportunities. Elkin Cancer Biology Seminar Series, Emory Univ. School of Medicine, Winship Cancer Institute, Atlanta, GA.
April 22, 2011 Changes in Cellular Signaling Pathways Measured by High Throughput
Screening. CBC Science Day, Prentice Women’s Hospital Conference Center, Chicago, IL.
June 8, 2011 PKCα is a Breast Cancer Biomarker. 17th International Charles
Heidelberger Symposium on Cancer Research. The Fourth Military Medical University In Xi’an, The People’s Republic of China.
August 16, 2011 PKCα: A Potential Breast Cancer Biomarker. Cancer Cell Signaling
Program, Cancer Center, UIC, Chicago, IL. February 14, 2013 Efficacy of Selective Estrogen Mimics for the Treatment of
PKCα Expressing Breast Cancer. Cancer Chemoprevention Program, Cancer Center, UIC, Chicago, IL
November 13, 2014 PKCα in Endocrine Resistant Breast Cancer: PDX Update. Breast Cancer
Symposium, UI Cancer Center, Chicago, IL.
November 20, 2014 Predictive Value of PKCα Expression in Breast Cancer. Department of
Pathology, COM, UIC. October 20, 2015 Establishment of a Relevant Breast Cancer Preclinical Model: Patient-
Derived Xenografts. UIC Cancer Center Research Day, Pilot Project Presentation.
March 14, 2016 Relevance of PKCα in Endocrine Resistant and Triple Negative Breast Cancer.
UIC College of Pharmacy Rockford Colloquium. May 27, 2016 Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant
Breast Cancer Using PKCalpha as a Predictive Biomarker. Charles Heidelberger Symposium on Cancer Research, Moscow, Russia.
February 15, 2017 Medical Scientist Training Program Dinner Seminar Series, UIC, Chicago,
IL. Laboratory Models of Endocrine Resistant Breast Cancer Provide Opportunities for Translation to the Clinic.
PEER-REVIEWED PUBLICATIONS https://www.ncbi.nlm.nih.gov/sites/myncbi/debra.tonetti.1/bibliography/48207265/public/?sort=date&direction=ascending
1. Druse, M. J., D. A. Tonetti and D. M. Smith, Jr. 1982. Effects of maternal nutritional stress
on synaptic plasma membrane proteins and glycoproteins in offspring. Exp. Neurol. 78:99-111.
2. Druse, M. J., G. M. Kelly, D. A. Tonetti, and B. G. Oden. 1986. Maternal ethanol consumption. Binding of L-glutamate to synaptic membranes from whole brain, cortices, and cerebella from offspring. Exp. Neurol. 91:219-228.
3. Tonetti, D. A., M. Horio, F. Collart, and E. Huberman. 1992. Protein kinase C β gene
expression is associated with susceptibility of human promyelocytic leukemia cells to phorbol ester induced-differentiation. Cell Growth & Differ. 3:739-745.
4. Tonetti, D. A., C. Henning-Chubb, D.T. Yamanishi, and E. Huberman. 1994. Protein kinase C
β is required for macrophage differentiation of human HL-60 leukemia cells. J. Biol. Chem. 269:23230-23235.
5. Tonetti, D.A., O'Regan, R., Tanjore, S., England, G. and Jordan, V.C. 1998. Antiestrogen
stimulated human endometrial cancer growth; laboratory and clinical considerations. J. Ster. Biochem. Mol. Biol.65: 181-189.
6. Levenson, A.S., Tonetti, D.A. and Jordan, V.C. 1998. The estrogen-like effect of 4-
hydroxytamoxifen (4-OHT) on induction of transforming growth factor alpha (TGFα) mRNA in MDA-MB-231 breast cancer cells stably expressing the estrogen receptor (ER). Br. J. Cancer 77:11 1812-1819.
7. Schafer, J.I.M, Liu, H., Tonetti, D.A. and Jordan, V.C. 1999. The interaction of raloxifene and the
active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor. Cancer Res.59: 4308-4313.
8. Tonetti, D.A., Chisamore, M., Grdina, W., Schurz, H. and Jordan, V.C. 2000. Stable
Transfection of Protein Kinase C Alpha cDNA in Hormone-Dependent Breast Cancer Cell Lines. Br. J. Cancer 83(6):782-791. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363523/
9. Fournier, D.B., Chisamore, M., Lurain, J., Rademaker, A., Jordan, V.C. and Tonetti,
D.A. 2001. Protein Kinase C Alpha Expression is Inversely Related to ER Status in Endometrial Carcinoma: Possible Role in AP-1 Mediated Proliferation of ER Negative Endometrial Cancer. Gyne Oncol., 81:366-372. https://doi.org/10.1006/gyno.2001.6164
10. Chisamore,M.J., Bentrem, D.B., Ahmed, Y., Jordan, V.C. and Tonetti, D.A. 2001. Novel
antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase C alpha. Clin. Cancer Res., 7: 3156-3165.
11. Tonetti, D.A., M. Morrow, N. Kidwai, A. Gupta, S. Badve. 2003. Elevated Protein Kinase C
Alpha Expression May Be Predictive of Tamoxifen Treatment Failure. British J. Cancer, 88: 1400-1402. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741052/
12. Liu, X., Pisha, E., Tonetti, D.A., Yao, D., Li, Y., Yao, J., Burdette, J.E. and Bolton, J.L. 2003.
Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. Chem. Res. Toxicol, 16: 832-837. https://doi.org/10.1021/tx030004s
13. Tonetti, D.A., Pike, R., Deleon, M., Zhao, H., Pappas, S.G., Bentrem, D., Chen, B.,
Constantinou, A. and Jordan, V.C. 2003. Stable transfection of an estrogen receptor beta cDNA into MDA-MB-231 breast cancer cells. J. Steroid Biochem. Mol. Biol. 87: 47-55.
14. Ee, P.L.R., Kamalakaran, S., Tonetti, D., He, X., Ross, D.D., and Beck, W.T. 2004.
Identification of a novel estrogen response element in the breast cancer resistance protein gene. Clin. Cancer Res., 64: 1247-1251.
15. Peng, X., Mehta, R.G., Tonetti, D.A, and Christov, K. 2005. Identification of novel RARβ2
transcript variants with short 5'-UTRs in normal and cancerous breast epithelial cells. Oncogene, 24(7):1296-301. https://doi.org/10.1038/sj.onc.1208284
16. Constantinou, A.I., White, B.E.P, Tonetti, D., Y. Wang, Liang, W., Li, W., van Breemen, R.B.
2005. The Soy Isoflavone Daidzein Improves the Capacity of Tamoxifen to Prevent Mammary Tumors. Eur. J. Cancer Res., 41(4):647-54. https://doi.org/10.1016/j.ejca.2004.12.005
17. Lin, X., Yu, Y., Zhao, H., Zhang, Y., Manela, J. and Tonetti, D.A. 2006. Overexpression of
PKCα is Required to Impart the Estradiol Inhibition and Tamoxifen Resistance in a T47D Human Breast Cancer Tumor Model. Carcinogenesis, 27(8):1538- 46.
https://doi.org/10.1093/carcin/bgl002
18. Tonetti, D.A., Zhang, Y., Zhao, Lee, S.B. and Constantinou, A. I. 2007. The effect of the phytoestrogens genistein, daidzein and equol on the growth of tamoxifen-resistant T47D/PKCα, Nutrition and Cancer, 58 (2): 222-229. https://doi.org/10.1080/01635580701328545
19. Rizzo, P., Miao, H., D’Souza, G., Osipo, C., Yun, J., Zhao, H., Mascarenhas, J., Wyatt, D.,
Hao, L., Yao, K., Rajan, P., Hicks, C., Siziopikou, K., Selvaggi, S., Koerner, F., Bashir, A., Bhandari, D., Marchese, A., Lendahl, U., Qin, J.-Z., Tonetti, D.A., Albain, K., Nickoloff ,B.J. and Miele, L. 2008. Cross-Talk Between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 68(13):5226-35. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445363/
20. Zhang, Y., Zhao, H., Asztalos, S., Chisamore, M.J., Sitabkhan, Y., Tonetti, D.A. 2009.
Estradiol-Induced Regression in T47D:A18/PKCα Tumors Requires the Extracellular Matrix and the Estrogen Receptor. Molecular Cancer Res., 7:498-510. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743931/
21. Asztalos, S., Gann, PH, Dai, Y., Hayes, M., Nonn, L., Beam, CA, Wiley, EL, Tonetti, DA.
2010. Gene Expression Changes in the Human Breast Following Pregnancy. Cancer Prevention Res.3(3):301-11. https://doi.org/10.1158/1940-6207.CAPR-09-0069
22. Kim, HY, Sohn, J., Kastrati, I., Edirisinghe, P., Molloy, ME, Tonetti, DA, Thatcher, GRJ.
2010. Click synthesis of estradiol-cyclodextrin conjugates as cell compartment selective estrogens. Bioorganic Med Chem, 15;18(2):809-21. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906776/
23. Halasi, M, Zhao, H, Dahari, H, Bhat, UG, Gonzalez, EB, Lyubimov, AV, Tonetti, DA,
Gartel, AL. 2010. Thiazole antibiotics against breast cancer. Cell Cycle, 9:6, 1214-1217. https://doi.org/10.4161/cc.9.6.10955
24. Tonetti, D.A., Gao, W, Escarzaga, D., Walters, K., Szafran, A.A. and Coon, J.S. 2012. PKCα
and ERβ are Associated with Triple-Negative Breast Cancers in African-American and Caucasian Patients. International Journal of Breast Cancer, vol. 2012. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299310/
25. Perez White, BE., Molloy, ME., Zhang, Y., Zhao, H., and Tonetti, DA. 2013. Extranuclear
ERα is Associated With Regression of PKCα-Overexpressing Tamoxifen- Resistant Breast Cancer, Molecular Cancer 12(1):34. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513358/
https://dx.doi.org/10.1186%2Fs12943-017-0697-5 In resubmission
26. Yun, J, Rizzo, P, Pannuti, A., Zhu, H., Hicks, C, Zhu, X., D’Souza, G., Backus, K., Denning, MF, Coon, J, Sun, M., Bresnick, EH, Osipo, C., Wu, J, Strack, P.R., Tonetti, DA and Miele, L. 2013. PKCα causes estrogen-independent breast cancer cell growth via AP-1/ Notch-
4/cyclin D1 pathway. Oncogenesis, Aug 5;2:e60. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759125/
27. Zheng,Y., Wang, Z., Bie, W., Brauer, P., Perez White, B., Li, J., Nogueira, V.,
Raychaudhuri, P., Hay, N., Tonetti, D. Macias, V., Kajdacsy-Balla, A. and Angela Tyner. 2013. Activation of Protein Tyrosine Kinase 6 at the Membrane Regulates the Epithelial Mesenchymal Transition in Prostate Cancer. Cancer Research. 73(17):5426- 37. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766391/
28. Maoyu Peng, Rajyasree Emmadi, Zebin Wang, Elizabeth L. Wiley, Peter H. Gann,
Seema Khan, Nilanjana Banerji, William McDonald, Szilard Asztalos, Thao N.D. Pham, Debra A. Tonetti, and Angela L. Tyner. 2014. PTK6/BRK is Expressed in the Normal Mammary Gland and Activated at the Plasma Membrane in Breast Tumors. Oncotarget, 15;5(15):6038-48. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171611/
29. Jamie C. Stanford, Christian Young, Donna Hicks, Philip Owens, Andrew Williams, David
B. Vaught, Meghan M. Morrison, Jiyeon Lim, Dana M. Brantley-Sieders, Justin M. Balko, Debra Tonetti, H. Shelton Earp III, and Rebecca S. Cook. 2014 The pro- metastatic landscape of the breast during post-partum involution is triggered by MerTK- mediated clearance of dying cells. J. Clin. Invest. 124(11):4737-52. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4347249/
30. Molloy ME, Perez White BE, Gherezghiher T, Michalsen BT, Xiong R, Patel H, Zhao H,
Maximov PY, Jordan VC Obe, Thatcher GR, Tonetti DA 2014. Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast. Mol Cancer Ther. 13(11):2515-26. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221411/
31. Weiss, MS., Peñalver Bernabé, B., Shin, S., Asztalos, S., Dubbery, S.J., Mui, M.D.,
Bellis, AD, Bluver, D., Tonetti, DA, Saez-Rodriguez, J, Broadbelt, LJ, Jeruss, JS. Shea, LD. 2014. Dynamic transcription factor activity and networks during ErbB2 breast oncogenesis and targeted therapy. Integrative Biology. Dec;6(12):1170-82. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237672/
32. Garth H Rauscher, Jacob K Kresovich, Matthew Poulin, Liying Yan, Virgilia Macias, Abeer
Mahmoud, Umaima Al-Alem, Andre A Balla, Elizabeth L Wiley, Debra Tonetti, Melanie Ehrlich. 2015. Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation. BMC Cancer, Oct 29,15:816. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625569/
33. Asztalos, S., Pham, T., Gann, PH.., Hayes, M.K., Deaton, R., Wiley, E.L., Emmadi, R.,
Kajdacsi-Balla, Banerji, N., McDonald, W., Khan, S.A., Tonetti, D.A. 2015. High incidence of triple negative breast cancers following pregnancy and an associated gene expression signature. SpringerPlus Breast Cancer Collection Nov 19;4:710 . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653130/
34. Xiong, R., Patel, H., Gutgesell, L., Zhao, J., Delgado-Rivera, L., Pham, T., Zhao, H., Carlson,
K., Martin, T., Katzenellenbogen, J.A.,, Moore, T., Tonetti, D., Thatcher, G. 2016 Selective
Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer. Journal of Medicinal Chemistry, 59(1):219-37. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779956/
35. Rui Xiong, Jiong Zhao, Lauren M. Gutgesell, Bhargava Karumudi, Huiping Zhao, Debra A.
Tonetti, and Gregory R. J. Thatcher. 2017. Novel Selective Estrogen Receptor Downregulators (SERDs) Developed Against Treatment Resistant Breast Cancer. Journal of Medicinal Chemisry, 60(4):1325-1342. https://doi.org/10.1021/acs.jmedchem.6b01355
36. Pham, T.N., Perez-White, B.E., Zhao, H. Mortazavi, F. and Tonetti, D.A. 2017. Protein Kinase
C Alpha enhances breast cancer cell migration through FOXC2-mediated repression of p120-catenin. BMC Cancer, 17(1):832. https://doi.org/10.1186/s12885-017-3827-y
INVITED REVIEWS
1. Tonetti, D. A. and V. C. Jordan. 1995. Possible mechanisms in the emergence of tamoxifen resistant breast cancer. Anti-Cancer Drugs 6:498-507.
2. Tonetti, D.A. and V.C. Jordan. 1996. Targeted anti-estrogens to treat and prevent diseases in
women. Mol. Med. Today. 2:218-223.
3. Tonetti, D.A. and V.C. Jordan. 1996. Design of an ideal hormone replacement therapy for women. Mol. Carcinogenesis. 17:108-111.
4. Jordan V.C., J.I. MacGregor and D.A. Tonetti. 1997. Tamoxifen: From breast cancer
therapy to the design of a postmenopausal prevention maintenance therapy. Osteoporosis Int. Suppl. 1:S52-S57.
5. Tonetti, D.A. and V.C. Jordan. 1997. The role of estrogen receptor mutations in tamoxifen-
stimulated breast cancer. Invited review, J. Ster. Biochem. Mol. Biol. 62: 119- 128.
6. Tonetti, D.A. and Jordan, V.C. 1999. The ER as a target for the prevention of breast cancer. Invited review, Journal of Mammary Gland Biology and Neoplasia, 4: 401-413.
7. Tonetti, D. A. Critical Commentary on “Phosphatidylinositol-3-OH kinase (PI3K)/AKT2,
activated in breast cancer, regulates and is induced by estrogen receptor α (ERα) via interaction between ERα and PI3K. Cancer Research, 2001, 61, 5985-5991.” Women Oncol Rev, 2002; 2: 151-152.
8. Tonetti, D. A. Critical Commentary on “A naturally occurring MTA1 variant sequesters
oestrogen receptor-α in the cytoplasm. Nature, 2002, 418:654-657. 2002.” Women Oncol Rev 2002; 2: 407-408.
9. Tonetti, D.A. Commentary: Prevention of breast cancer by recapitulation of pregnancy hormone levels. Breast Cancer Res 2004, 6:E8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC314461/
10. Pham, T.N. and Tonetti, D.A. The role of protein kinase C alpha (PKCα) in breast cancer: A
focus on endocrine resistant and triple negative subtype. Journal of Cancer Biology & Research 2016, 4(1): 1076. https://www.jscimedcentral.com/CancerBiology/cancerbiology-4-1076.pdf
BOOK CHAPTERS
1. Benbrook, D. M., D. A. Tonetti and R. V. Miller. 1989. DNA gyrase of Pseudomonas aeruginosa: Inhibition by quinolones. p. 171-186. In P. B. Fernandes, D. T. W. Chu, L. Shen, P. Fernandes, L. O. White and G. K. Daikos (eds.), Quinolones, Proceedings of an International Telesymposium, J. R. Prous Science Pub. Barcelona, Spain.
2. Huberman, E., D. A. Tonetti, M. Horio, S. Murao, and F. R. Collart. 1993. The control of cell
multiplication and differentiation in human myelomonocytic cells. In N. D'Alessandro, E. Mihich, L. Rausa, H. Tapiero, and T. R. Tritton (eds.), Specific Approaches in Cancer Therapy: Differentiation, Immunomodulation and Angiogenesis NATO ASI Series, 75:17- 32.
3. Collart, F.R., D.A. Tonetti, E. Huberman. 1996. The control of multiplication and
differentiation in human myelomonocytic leukemia cells. In A.S Tsiftsoglou, A.C. Sartorelli, D.E. Houseman and T.M. Dexter (eds.) Tumor Biology: Regulation of Cell Growth, Differentiation and Genetics in Cancer NATO ASI Series, H99: 113-128.
4. Tonetti, D.A. and V.C. Jordan. 1997. Targeted Antiestrogens. In Aldaz, M. (ed.),
Etiology of Breast and Gynecological Cancers, Wiley-Liss, Inc., New York, 245-255.
5. Jordan V.C., J.I. MacGregor and D.A. Tonetti. 1997. Can the new prevention strategies reduce the incidence of ductal carcinoma in situ? In M.J. Silverstein (ed) Ductal Carcinoma in Situ of the Breast, Williams & Wilkins, Baltimore, MD, 625-629.
6. MacGregor J., Tonetti, D.A. and Jordan V.C. 1997. The complexity of selective estrogen
receptor modulation: the design of a postmenopausal prevention maintenance therapy. In R. Lindsay, D. Dempster and V.C. Jordan (eds) Estrogens and Antiestrogens, Lippincott- Raven Publishers, Philadelphia, PA, 261-277.
7. Gajdos, C., MacGregor, J.I., Tonetti, D.A. and Jordan, V.C. 2002. Can the New Prevention
Strategies Reduce the Incidence of Ductal Carcinoma In Situ? In M.J. Silverstein (ed) Ductal Carcinoma in Situ of the Breast, Lippincott, Williams & Wilkins, Philadelphia, PA, 497-501.
8. Pham, T.N.D. and Tonetti, D.A. 2017. Protein Kinase C Signaling in Carcinogenesis. In SS Badve and GL Kumar (eds) Predictive Biomarkers in Oncology: Applications in Precision Medicine., In Press.
ABSTRACTS 1. Druse-Manteuffel, M., M. Collins, D. Tonetti, C. Waddell, and P. Patel. 1981. Phenylketonuria
(PKU), tetrahydroisoquinolines (TIQs) and neurological damage. Neuroscience Abs.
2. Laten, H. M., S. Zahareas-Doktor, D. A. Tonetti, M. Quinn, R. M. Timmons, and C. Van Kast. 1984. Synthesis and metabolism of isopentenyladenosine in yeast. American Society for Microbiology.
3. Druse-Manteuffel, M. J., G. M. Kelly, D. A. Tonetti, and B. G. Oden. 1984. L-glutamate binding
to synaptic membranes: Influence of maternal ethanol consumption. Neurscience Abs. 4. Benbrook, D. M., D. A. Tonetti, and R. V. Miller. 1985. Inhibition of Pseudomonas
aeruginosa DNA gyrase by norfloxacin. Interscience Conference on Antimicrobial Agents and Chemotherapy.
5. Tonetti, D. A. and R. V. Miller. 1988. Cloning and characterization of a DNA fragment
containing a gyrA analog from Pseudomonas aeruginosa PAO. American Society for Microbiology.
6. Tonetti, D. A. and R. V. Miller. 1989. Analysis of the Pseudomonas aeruginosa qin gene: A
possible gyrA analog. Pseudomonas '89 Abs. 7. Tonetti, D. A., M. Horio and E. Huberman. 1992. Protein kinase C isotype expression in PMA-
sensitive and PMA-resistant HL-60 cell variants. American Association for Cancer Research. 8. Tonetti, D. A., M. Horio, and E. Huberman. 1993. Protein kinase C ® plays an essential role in
human HL-60 leukemia cell differentiation induced by phorbol diesters. American Association for Cancer Research.
9. Tonetti, D. A., C. Henning-Chubb, D. T. Yamanishi, and E. Huberman. 1994. Restoration of
susceptibility to differentiation induction by PMA in a PMA-resistant HL-60 cell variant by transfection with PKC ® cDNA. J. Cell. Biochem. Suppl. 18D Wiley-Liss, Inc., New York.
10. Tonetti, D.A., Henning-Chubb, C. and Huberman, E. 1995. Electroporation lends clues to the
PMA-induced transduction pathway leading to human promyelocytic HL-60 leukemia macrophage differentiation. American Association for Cancer Research.
11. Levenson, A.S., Tonetti, D.A., and Jordan, V.C. 1996. Paradoxical expression of transforming
growth factor 〈 (TGF〈) mRNA in MDA-MB-231 cells transfected with the estrogen receptor (ER). American Association for Cancer Research.
12. Tellez, C., Tonetti, D.A., Tanjore, S., and Jordan, V.C. 1996. A study of the structure- function
relationship of pS2 and c-fos estrogen response elements (ERE) by modification of the vitellogenin ERE. American Association for Cancer Research.
13. V. C. Jordan, Z. Chen, A.S. Levenson, J.I. MacGregor, H.D. Muenzner, S.B. Tanjore, D.A. Tonetti and J.T. Yang. 1997. The regulation of transforming growth factor (TGF) 〈.
14. Tonetti, D.A. and V.C. Jordan. 1997. PKC isozyme in hormone-independent breast cancer.
20th Annual San Antonio Breast Cancer Symposium. 15. Tonetti, D.A., W. Grdina, H. Schurz, M. Chisamore, and V.C. Jordan. 1998. The role of
PKCα overexpression in hormone-nonresponsive breast cancer. 21st Annual San Antonio Breast Cancer Symposium.
16. O’Regan, R., Tonetti, D.A. and Jordan, V.C. 1998. Comparison of tamoxifen and raloxifene
on the growth of endometrial cancer cell lines. 21st Annual San Antonio Breast Cancer Symposium.
17. Chisamore,M.J., Lee, E.S., Jordan, V.C. and Tonetti, D.A. 2000. Novel antitumor effect of
estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase c alpha. American Association for Cancer Research.
18. Fournier, D.B., Chisamore, M.J., Rademaker, A.W., Lurain, J.R., Jordan, V.C. and Tonetti, D.A.
2000. Examination of protein kinase c expression as a possible prognostic factor in endometrial carcinoma. American Association for Cancer Research.
19. Tonetti, D.A. M.J. Chisamore, Y. Ahmed and V.C. Jordan. 2001. PKC alpha is highly
expressed in T47D and MCF7 tumor models that regress upon estradiol administration. American Association for Cancer Research.
20. Tonetti, D.A., Morrow, M., Kidwai, N, Gupta, A., and Badve, S. 2001. Elevated protein kinase C
alpha expression may be predictive of tamoxifen treatment failure. Accepted. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics. Oct 29-Nov 2.
21. Manela, J., Chisamore, M.J., Jordan, V.C. and Tonetti, D.A. 2001. Is Overepression of Protein
Kinase C Alpha Required to Induce a Hormone-Independent Phenotype inT47D Breast Cancer Cells. 24th Annual San Antonio Breast Cancer Symposium, Dec 10-13.
22. Tonetti, D.A., Pike, R., Pappas, S.G., Bentrem, D., Chen, B., Jordan, V.C. 2002. MDA- MB-231
estrogen receptor beta stable clones exhibit distinct growth and transcriptional characteristics. 25th Annual San Antonio Breast Cancer Symposium, Dec 10-14.
23. Pappas, S.G., Bentrem, D.J., Gajdos, C., Tonetti, D.A., Jordan, V.C. 2002. The shape of the
estrogen receptor (ER)-ligand complex predicts the agonist and antagonist actions of endocrine disrupters in target tissues. 25th Annual San Antonio Breast Cancer Symposium, Dec 10-14.
24. Constantinou, A.I., Tonetti, D.A., Callegari, E.A., White, B.E.P., Chelminska, A., Patel, H.,
and Lantvit, D. 2003. Soy protein isolate, but not genistein, enhances the chemopreventive effects of tamoxifen against DMBA-induced mammary tumors in female rats. American Association for Cancer Research, July 11-14, Washington D.C.
25. Tonetti, D.A., Lin, X., and Zhao, H. 2003. Signal transduction pathways involved in estradiol-
induced regression and tamoxifen-resistance in T47D:A18/PKC〈 tumors. American Association of for Cancer Research Advances in Breast Cancer Research, October 8-12, Huntington Beach, CA.
26. Tonetti, D.A., Chisamore, M.J., Ahmed, Y., Zhao, H., Zhang, Y. and Sztark, A. 2003.
Mechanism of estradiol-induced regression of T47D:A18/PKC〈 tumors involve the estrogen receptor and interaction with the extracellular matrix. 26th Annual San Antonio Breast Cancer Symposium, Dec. 3-6, San Antonio, TX.
27. Lin, X., Yu, Y., DeLeon, M., and Tonetti, D.A. 2004. Overexpression of PKC alpha is required
to impart the hormone-independent phenotype in T47D. Minisymposium, American Association for Cancer Research, March 27-31, Orlando, FL.
28. Lin, X., Yu, Y., Zhao, H., Nasr, M. and Tonetti, D.A. 2005. Gene expression profiling in estradiol-
induced T47D/PKCα tumor regression. American Association for Cancer Research. April 16-20, Anaheim, CA.
29. Zhang, Y., Zhao, H. and Tonetti, D.A. 2005. Raloxifene effectively inhibits the growth of
tamoxifen resistant T47D:A18/PKC〈 tumors. 28th Annual San Antonio Breast Cancer Symposium, Dec. 8-11, San Antonio, TX.
30. Tonetti, D.A., Beam, CA, Gao, W, Escarzaga, D., and Coon, J.S. 2006. PKCα expression in
African-American and Caucasian breast cancer patients. American Association for Cancer Research. April 1-5, Washington, D.C.
31. Zhang, Y. and Tonetti, D.A. 2006. Changes in integrin expression are associated with estradiol-
induced T47D:A18/PKCα tumor regression. American Association for Cancer Research. April 1-5, Washington, D.C.
32. Yun J, Denning, M., Tonetti DA, Miele L. Crosstalk between PKC〈 and Notch-4 in
tamoxifen-resistant breast cancer. 29th Annual San Antonio Breast Cancer Symposium. Dec 14-17, 2006.
33. Rizzo, P., Yun, J., Hao, L., Tonetti, DA, Albain, K. and Miele, L. Cross talk between Notch
signaling and the estrogen receptor alpha in breast cancer suggests new therapeutic strategies. 29th
Annual San Antonio Breast Cancer Symposium. Platform presentation. Dec 14-17, 2006.
34. Zhang, Y., Zhao, Lee, S-B, Constantinou, A., Tonetti, D.A. The effect of isoflavones on the growth of T47D/PKCα tamoxifen-resistant breast cancer. American Association for Cancer Research, Los Angeles, CA, April 14-18, 2007.
35. Zhang, Y., Zhao, H., Tonetti, D.A., Estradiol and bovine serum albumin conjugated estradiol
inhibit the growth of T47D/PKCα cells in 3-D cell culture. American Association for Cancer Research, Los Angeles, CA, April 14-18, 2007.
36. White, B., Vraka, P., Tonetti, D.A., and Constantinou, A.I. Equol increases the in vitro efficacy
of tamoxifen. American Association for Cancer Research, Los Angeles, CA, April 14-18, 2007.
37. Yun J, Denning MF, Bresnick E, Tonetti DA, Miele L Protein Kinase C alpha regulates Notch-4 signaling via AP-1 in tamoxifen resistant breast cancer. American Association for Cancer Research, Los Angeles, CA, April 14-18, 2007.
38. Zhang, Y., Asztalos, S., Zhao, H., and Tonetti, D.A. Gene expression regulated by estradiol
and fulvestrant in T47D/PKCα tumors. American Association for Cancer Research, San Diego, CA, April 12-16, 2008.
39. Asztalos, S., Gann, P., Hayes, M., Nonn, L., Beam, C., Wiley, E. and Tonetti, D. Role of lobular
involution in pregnancy-associated breast cancer. CTRC-AACR San Antonio Breast Cancer Symposium. Dec. 10-14, 2008.
40. White, B., Zhao, H. and Tonetti, D.A. Overexpression of PKCα in T47D:A18 cells results in a
noninvasive phenotype. American Association for Cancer Research, Denver, CO, April 18-22, 2009.
41. Kundu, M., Zhang, Y., Zhao, H. and Tonetti, D.A. Estradiol induced regression of
T47D:A18/PKCα tumor involves translocation of estrogen receptor alpha from the nucleus to the cytoplasm. CTCR-AACR San Antonio Breast Cancer Symposium. Dec 9-13, 2009.
42. Perez-White, B and Tonetti, D.A. T47D/PKCα cells are nonmigratory and noninvasive in vitro
despite tamoxifen resistance in vivo. CTCR-AACR San Antonio Breast Cancer Symposium. Dec 9-13, 2009.
43. Asztalos, S., Gann, P.H., Hayes, M.K., Nonn, L., Wiley, E.L., Khan, S.A., Susnik, B., Diaz,
L.K., Banerji, N., and Tonetti, D.A. Increased expression of inflammatory genes in pregnancy- associated breast cancers. CTCR-AACR San Antonio Breast Cancer Symposium. Dec 9- 13, 2009.
44. Molloy, ME, Thatcher, GRJ, Bolton, JL and Tonetti, D.A. 2-(4-hydroxyphenyl)-
benzo[b]thiophen-6-ol, an estrogen-like compound, induces apoptosis in T47D/PKCα breast cancer cells. CTCR-AACR San Antonio Breast Cancer Symposium. Dec 9-13, 2009.
45. Han, H. Frasor, J. and Tonetti, D.A. Overexpression of PKCα alters gene expression pattern in T47D breast cancer cells associated with hormone-independent growth and tamoxifen resistance. American Association for Cancer Research, Washington, D.C., April 17-21, 2010.
46. Tonetti, D.A., Asztalos, S., Gann, P., Hayes, M., Nonn, L., Wiley, E., Khan, SA, Susnik, B., Diaz
L., Banerji, N. and Joshi, R. Gene Expression Patterns in Pregnancy-Associated Breast Cancer. Gordon Research Conference, Mammary Gland Biology. Lucca (Barga) Italy, June 6-11, 2010.
47. White, BEP, Zhao. H. and Tonetti, DA. Overexpression of PKCα in T47D breast cancer cells
induces migration via p120-catenin transcriptional downregulation. American Association for Cancer Research, Orlando, FL, April 2-6, 2011.
48. Molloy, ME and Tonetti, D.A. Potential role for Src kinase inhibitors in PKCα- overexpressing breast cancer. American Association for Cancer Research, Orlando, FL, April 2-6, 2011.
49. Asztalos, A., Gann, PH, Nonn, L, Balla, AK, Macias, V, Deaton, RJ, Wiley, E and Tonetti, DA.
The effects of pregnancy on ERα and Her2/neu protein expression in the normal breast. American Association for Cancer Research, Orlando, FL, April 2-6, 2011.
50. Kundu M, Zhang Y, Zhao H and Tonetti DA. Extranuclear ERα plays an important role in
estradiol-induced regression of T47D:A18/PKCα tumors. American Association for Cancer Research, Orlando, FL, April 2-6, 2011.
51. Rauscher GH, Ahsan H, Kibriya M, Dai Y, Wiley E, Kajdacsy-Balla A, Macias V, Levenson V,
Tonetti D, Ehrlich M. DNA methylation and hormone receptor status in breast cancer. 3rd North American Congress of Epidemiology, Montreal, Quebec, Canada, June 23, 2011.
52. White, BE and Tonetti, DA. PKCα regulates FOXC2 expression in T47D breast cancer cells.
Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications, Oct 12, 2011.
53. Molloy, ME and Tonetti, DA. Overexpression of PKCα in T47D breast cancer cells alters the CD44high/CD24low population. Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications, Oct 12, 2011.
54. Perez White BE, Zhao, H., Kundu, M., Molloy, ME and Tonetti DA. Protein kinase C α
overexpression is associated with loss of membrane-associated E-cadherin and β-catenin in T47D xenograft breast tumors. American Association for Cancer Research, Chicago, IL, March 31-April 4, 2012.
55. Rauscher G and Tonetti, D. Potential role for hormonal and reproductive factors in explaining
ethnic/racial disparities in breast cancer aggressiveness. Society for Epidemiologic Research, Minneapolis, MN, June 27-30, 2012.
56. Pham, Thao Nguyen, Asztalos, S., Weiss, M.S., Shea, L.D. and Tonetti, D.A. Overexpression of
protein kinase C alpha differentially activates transcription factors in T47D breast cancer cells in presence of 17β-estradiol both in the 2D and 3D environments. CTCR-AACR San Antonio Breast Cancer Symposium, Dec 4-8, 2012.
57. Espinoza, I, Pannuti, A. Caskey, M., Papa, F., Russell, R., Xhu, X., Hicks, C., Wang, G. Tonetti,
D. and Miele, L. Paralog-specific effects of Notch1 and Notch4 in endocrine- resistant, ERα+ breast cancer cells: therapeutic implications. Submitted to The Notch Meeting VII, Athens, Greece, October 2013.
58. Mary Ellen Molloy, Bethany Perez White, Huiping Zhao, Bradley T. Michalsen, Hitisha
K. Patel, Jiong Zhao, Rui Xiong, Marton I. Siklos, Gregory R.J. Thatcher, Debra A. Tonetti. Selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer. AACR San Diego, CA April 7 2014.
59. Hitisha Patel, Rui Xiong, Jiong Zhao, Mary Ellen Molloy, Debra Tonetti, Gregory R.J Thatcher. Lead based development and evaluation of selective estrogen mimics in tamoxifen resistant breast
cancer. AACR San Diego, CA April 7 2014.
60. Thao N.D. Pham, Szilard Asztalos, Peter H. Gann, Meghan K. Hayes, Ryan Deaton, Elizabeth L. Wiley, Rajyasree Emmadi, Andre Kajdacsi-Balla, Nilanjana Banerji, Willam McDonald, Seema A. Khan, Debra A. Tonetti. High Incidence Of Triple Negative Breast Cancers Following Pregnancy And The Associated Gene Expression Signature. Illinois Symposium on Reproductive Sciences, Chicago, Oct 13, 2014.
61. G. Thatcher, R. Xiong, H.K. Patel, J. Zhao, X. Liang, Y. Wang, M.E. Molloy, D. Tonetti Potent,
partial agonists at ERalpha as selective estrogen mimics for treatment of tamoxifen-resistant breast cancer. EORTC-NCI-AACR, Barcelona, Spain, Nov. 18-21, 2014.
62. Gregory R. J. Thatcher, Rui Xiong, Hitisha K. Patel, Jiong Zhao, Xiao Liang, Yue-ting Wang,
Mary Ellen Molloy, and Debra Tonetti. Novel, non-uterotrophic, selective estrogen mimics cause regression of tamoxifen-resistant breast cancer in 2D and 3D cultures and in mouse xenograft models. CTCR-AACR San Antonio Breast Cancer Symposium, Dec 9-12, 2014.
63. Thao Pham, Bethany Perez-White and Debra A. Tonetti. Protein Kinase C alpha (PKCα) is a
novel regulator of FOXC2 and p120-catenin in triple negative and endocrine resistant breast cancer. American Association for Cancer Research, Philadelphia, April 18, 2015.
64. Huiping Zhao, Thao Pham, Rajyasree Emmadi, Elizabeth Wiley, Michael Warso, Alejandra
Perez-Tamayo, George Salti, Kent Hoskins, and Debra A. Tonetti. Breast Cancer Patient-Derived Xenografts: The University of Illinois at Chicago Cancer Center Experience. AACR: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic, New Orleans, February 11-14 2016.
65. Thao ND Pham, Bethany PE White, and Debra A Tonetti. PKCα mediates FOXC2 transcriptional repression of p120-catenin in breast cancer. American Association for Cancer Research, New Orleans, April 2016.
66. Gutgesell, Lauren; Xiong, Rui; Tonetti, Debra; Thatcher, Gregory. Combination therapy of
targeted anticancer pathways and estrogen receptor ligands and their responses in de novo and tamoxifen resistant cell models. CTCR-AACR San Antonio Breast Cancer Symposium, Dec. 6-10 2016.
67. Gutgesell, Lauren; Xiong, Rui; Tonetti, Debra; Thatcher, Gregory. Combination therapy
targeting endocrine therapy-resistance in estrogen receptor positive breast cancer. American Association for Cancer Research, Washington DC, April 4, 2017.
68. Tonetti, D.A., Xiong, R., Zhao, J., Gutgesell, L.M., Dudek, A., Thatcher, G.R.J. Efficacy,
Maximal Tolerated Dose, and Toxicokinetics of TTC-352 in Rats and Dogs, a Partial ER Agonist for Metastatic ER+ Breast Cancer. American Society for Clinical Oncology, Chicago, June 2-5, 2017.